New IBD treatment shows promise in Real-World patient study
NCT ID NCT07273760
Summary
This study followed 150 patients with inflammatory bowel disease (including Crohn's disease and ulcerative colitis) who received Vedolizumab treatment as part of their regular medical care. Researchers tracked how well the treatment worked and monitored for side effects over one year. The goal was to understand how this medication performs in everyday clinical practice rather than in a controlled trial setting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr. Ali Beheshti-Namdar Clinic
Mashhad, Razavi Khorasan Province, Iran
-
Dr. Hamid Asadzadeh Aghdaei Clinic
Tehran, Iran
-
Dr. Hassan Vossoughinia Clinic
Mashhad, Razavi Khorasan Province, Iran
-
Dr. Mahtab Shabani Clinic
Tehran, Iran
-
Dr. Mohammad-Javad Kaviani Clinic
Shiraz, Fars, Iran
-
Dr. Naser Ebrahimi Daryani Clinic
Tehran, Iran
-
Gilan Gastroenterology and Hepatology Subspecialty Clinic
Rasht, Gilan Province, Iran
-
Imam Khomeini Hospital
Tehran, Iran
-
Mehr Specialty Clinic
Tehran, Iran
-
Professor Shahram Agah Gastroenterology, Hepatology, and Endoscopy Subspecialty Clinic
Tehran, Iran
-
Shariati Hospital
Tehran, Iran
-
Taleghani Hospital
Tehran, Iran
Conditions
Explore the condition pages connected to this study.